Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion - Plain language summary

Sep 23, 2026

Plain language summary describing a study of children with sarcoma whose cancer was controlled with larotrectinib, a targeted anti-cancer medicine for TRK fusion cancers. The study examined outcomes after pausing treatment: whether the cancer started growing again or returned, and whether restarting larotrectinib could regain control. Among 47 children, 31 maintained well-controlled disease after stopping, while 16 showed worsening and often improved after resuming therapy.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages10

Reading Time25 min

AccessFree to download

Where can I find the original article on which this summary is based?

What is this summary about?

What are the key takeways?

What were the main conclusions reported by the researchers?

What is the purpose of this plain language summary?

Who is this article for?

Who sponsored this study?

Why was this study carried out?

Future ONCOLOGY Plain Language Summary of Publication Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion: a plain language summary Leo Mascarenhasa , Christopher Ollisb,c, Yuvraj Singhd, Linet Menacherye, Domnita-Ileana Burcoveanuf, Esther De La Cuestag , Cornelis M van Tilburgh,i,j, k & Theodore W Laetschl Author affiliations can be found at the end of this article. First draft submitted: 26 May 2026; Accepted for publication: 27 July 2026 Where can I find the original article on which this summary is based? The original article is titled ‘Elective discontinuation of larotrectinib in pediatric patients with TRK fusion sarcomas and related mesenchymal tumors’. You can read the original article for free at: [https://ascopubs.org/doi/10.1200/JCO.24.00848](https://ascopubs.org/doi/10.1200/JCO.24.00848) What is this summary about? This plain language summary describes a study that looked at children with a type of cancer called ‘sarcoma’ and it explains what happened when they stopped taking larotrectinib treatment. Larotrectinib is a targeted anti-cancer medication that treats cancers known as ‘TRK fusion cancers’, which are cancers that have a characteristic type of genetic change that is not normal. Anti-cancer treatments should control cancer, ideally by removing all traces of How to say (download PDF and double click sound icon to play sound) ... • Larotrectinib: LAR-oh-TREK-tih-nib • Mesenchymal: meh-SEN-kai-muhl • NTRK: EN-track or EN-trek • Sarcoma: sar-KO-muh • TRK: track or trek cancer from the body; if this is not possible, an effective treatment should shrink the tumor or at least prevent further growth. It is important to understand how long a child should stay on larotrectinib once the TRK fusion cancer has become well controlled on this treatment. This study looked at whether stopping larotrectinib treatment had any effect on control of the cancer, whether the cancer started to grow after larotrectinib was stopped, and if resuming larotrectinib treatment could control the cancer again. What are the key takeways? In a group of 47 children in whom the cancer was controlled with larotrectinib, the cancer remained well controlled after stopping treatment in 31 children (about 2 in every 3 of the overall group) . The remaining 16 children had signs of their cancer getting worse, so they resumed larotrectinib. In 15 of these children, resuming larotrectinib controlled the cancer again. The remaining 1 child had surgery shortly after resuming larotrectinib, so it was not possible to clearly tell how much resuming treatment helped after surgery; however, the cancer remained controlled without taking any more larotrectinib after surgery. 10. 1080/14796694 .2026. 2711519 © 2026 The Author(s) . Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. For reprints and re-use requests, please contact: [t&freprints@tandf.co.uk](t&freprints@tandf.co.uk) ISSN 1744-8301 Future Oncol. (2026) 22(19), 2233–2242 2233 Plain Language Summary of Publication Mascarenhas, Ollis, Singh and co-authors What were the main conclusions reported by the researchers? Children with TRK fusion sarcoma treated with larotrectinib may be able to stop this treatment once the cancer is controlled. For children who stop larotrectinib treatment, if the cance

FAQs

What treatment did the study look at stopping and restarting?

The study evaluated pausing larotrectinib in children whose TRK fusion sarcoma was responding, and then restarting larotrectinib if the cancer began to worsen or return.

What happened to the cancer after larotrectinib was paused?

In 31 of 47 children, the cancer stayed well controlled after stopping larotrectinib. In the remaining 16 children, signs suggested the cancer was worsening, and treatment was resumed.

If larotrectinib was resumed, did it control the cancer again?

In 15 of the children who restarted larotrectinib, restarting treatment controlled the cancer again. One child had surgery shortly after restarting, so the benefit from restarting alone could not be clearly determined, though the cancer remained controlled afterward.

Sep 23, 2026

Uploaded by anakgang17